<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04246905</url>
  </required_header>
  <id_info>
    <org_study_id>2019209</org_study_id>
    <nct_id>NCT04246905</nct_id>
  </id_info>
  <brief_title>A 12-weeks Study to Evaluate Sulforaphane in the Treatment of Depression</brief_title>
  <official_title>Efficacy of Adjunctive Sulforaphane for Depression: Study Protocol for a Randomized, Double-blind, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central South University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Major depressive disorder is a serious, recurrent and disabling mental disorder, which is the
      second leading cause of years lost to disability worldwide. Accumulating evidence suggests
      the important role for inflammation and oxidative stress in the pathophysiology of
      depression. Sulforaphane extracted from broccoli sprout is an agent with potent anti-oxidant
      and anti-inflammatory activity. Previous studies suggested sulforaphane activates Keap1-Nrf2
      system to prevent depression-like phenotype in mice. In this study, the investigator attempts
      to evaluate the efficacy, safety, and tolerability of sulforaphane plus a fixed oral
      antipressant in adult participants diagnosed with depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 90 patients aged 18-55 years with depression will be included, all of whom gave
      informed consent. Participants will receive 12 weeks of either sulforaphane or placebo per
      day, in addition to the existing treatment. Baseline assessments include demographics, a
      comprehensive medical history, anthropometric measurements (weight and height), physical
      examination, and lab work. Clinical symptoms will be assessed by the Montgomery-A° sberg
      Depression Rating Scale (MADRS), Hamilton depressive scale (HAMD), Hamilton Anxiety
      Scale(HAMA), and Patient Health Questionnaire-9 (PHQ-9). The safety will be assessed by
      Treatment Emergent Symptom Scale (TESS). The cognitive function will be evaluated by MATRICS
      Consensus Cognitive Battery （MCCB）at the beginning of the study and at week 12. The cranial
      MRI is examined at baseline and repeated at week 12. The primary outcomes will be the
      effective time and the percentages of efficacy at 8 weeks, measured using the MADRS. Efficacy
      is defined as ≥50% decreases in the total score of MADRS. Secondary outcomes include global
      psychopathology, quality of life, functioning, cognition, biological data, safety and
      tolerability.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be treated with sulforaphane or placebo for 12 weeks after ramdomization.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Participants and researchers are blind to treatment allocation (double-blind). An independent researcher developed the computer-generated randomization plan.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline Montgomery-A° sberg Depression Rating Scale (MADRS) total score at week 8</measure>
    <time_frame>baseline and week 8</time_frame>
    <description>Range from 0-60, higher score indicates more severe symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of Hamilton depressive scale (HAMD) from baseline to week 12</measure>
    <time_frame>Week 0 and week 12.</time_frame>
    <description>Range from 24-75, higher score indicates more severe symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the total scores of Hamilton depressive scale (HAMD)</measure>
    <time_frame>Week 0, 2, 4, 6, 8, 12.</time_frame>
    <description>Range from 24-75, higher score indicates more severe symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Anxiety Scale(HAMA)</measure>
    <time_frame>Week 0, 2, 4, 6, 8, 12.</time_frame>
    <description>Range from 0-56, higher score indicates more severe symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The total score of clinical global impression-severty of illness (CGI-SI)</measure>
    <time_frame>Week 0, 2, 4, 6, 8, 12.</time_frame>
    <description>Range from 0-7, higher score indicates more severe symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of MATRICS Consensus Cognitive Battery （MCCB）from baseline to week 12</measure>
    <time_frame>Week 0, 12.</time_frame>
    <description>To evaluate the efficacy of adjunctive sulforaphane treatment in improving cognitive functions. Higher score indicates better cognition</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>sulforaphane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sulforaphane treatment arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sulforaphane</intervention_name>
    <description>To examine the add-on effect of sulforaphane in depression patients with escitalopram treatment</description>
    <arm_group_label>sulforaphane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placedo</intervention_name>
    <description>To examine the add-on effect of sulforaphane in depression patients with escitalopram treatment</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>To examine the add-on effect of sulforaphane in depression patients with escitalopram treatment</description>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_label>sulforaphane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-55 years old

          -  Clinical diagnosis of recurrent MDD or single-episode MDD with MADRS≥22, CGI-SI≥4

          -  be adherent to the continued oral antidepressant treatment medication

        Exclusion Criteria:

          -  treatment-resistant depression

          -  have known allergies, hypersensitivity, intolerance, or contraindications to
             escitalopram or any of the trial preparations

          -  strong homicidal ideation/intent

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Renrong Wu, M.D. Ph.D</last_name>
    <phone>+8615874179855</phone>
    <email>wurenrong@csu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jing Huang, M.D.</last_name>
    <email>jinghuangserena001@csu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mental Health Institute of Second Xiangya Hospital,CSU</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 6, 2020</study_first_submitted>
  <study_first_submitted_qc>January 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2020</study_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central South University</investigator_affiliation>
    <investigator_full_name>Renrong Wu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Sulforaphane</keyword>
  <keyword>Depression</keyword>
  <keyword>Fatigue</keyword>
  <keyword>Cognition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulforafan</mesh_term>
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

